Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 48 million

Carnegie acted as financial adviser in the directed new share issue of 5.2 million new shares at a price of SEK 9.30 per share. Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. October, 2011.